- Home
- APLT vs INTS Comparison
APLT vs INTS Comparison
Compare APLT & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- INTS
- Stock Information
- Founded
- APLT 2016
- INTS 2012
- Country
- APLT United States
- INTS United States
- Employees
- APLT N/A
- INTS N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- INTS Health Care
- Exchange
- APLT Nasdaq
- INTS Nasdaq
- Market Cap
- APLT 37.5M
- INTS 30.8M
- IPO Year
- APLT 2019
- INTS 2023
- Fundamental
- Price
- APLT $0.33
- INTS $1.85
- Analyst Decision
- APLT Buy
- INTS Strong Buy
- Analyst Count
- APLT 7
- INTS 3
- Target Price
- APLT $6.10
- INTS $8.50
- AVG Volume (30 Days)
- APLT 2.3M
- INTS 15.7K
- Earning Date
- APLT 04-14-2025
- INTS 05-08-2025
- Dividend Yield
- APLT N/A
- INTS N/A
- EPS Growth
- APLT N/A
- INTS N/A
- EPS
- APLT N/A
- INTS N/A
- Revenue
- APLT $455,000.00
- INTS N/A
- Revenue This Year
- APLT $3,031.87
- INTS N/A
- Revenue Next Year
- APLT $312.01
- INTS N/A
- P/E Ratio
- APLT N/A
- INTS N/A
- Revenue Growth
- APLT N/A
- INTS N/A
- 52 Week Low
- APLT $0.30
- INTS $1.50
- 52 Week High
- APLT $10.62
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- APLT 36.05
- INTS 38.40
- Support Level
- APLT $0.30
- INTS $1.78
- Resistance Level
- APLT $0.38
- INTS $2.00
- Average True Range (ATR)
- APLT 0.05
- INTS 0.14
- MACD
- APLT -0.00
- INTS -0.00
- Stochastic Oscillator
- APLT 17.19
- INTS 24.22
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.